Sean Marett
Corporate Officer/Principal bei BIONTECH SE
Vermögen: 75 Mio $ am 31.03.2024
Profil
Sean Marett is currently the Chairman at PHMR Ltd.
He is also the Co-Managing Director at JPT Peptide Technologies GmbH.
In addition, he holds the position of Chief Business & Commercial Officer at BioNTech SE since 2012.
Recently, he became a Member-Supervisory Board at Aicuris Anti-Infective Cures AG in 2021.
Previously, Mr. Marett served as a Director at Lorantis Ltd.
He was a Non-Executive Director at KWS BioTest Ltd.
from 2011 to 2018.
He also held the position of Director at Mann Bioinvest Ltd.
from 2013 to 2016.
Additionally, he worked as a Principal at Wyeth LLC, Pfizer Inc., and GSK Plc.
He served as the Chief Business Officer at Evotec SE and as the Senior Vice President-Business Development at NextPharma Technologies Ltd.
Furthermore, he was the Chief Operating Officer at BioNTech SE and a Principal at UCB Celltech.
Mr. Marett completed his undergraduate studies at King's College London.
He also holds an MBA from Manchester Business School.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
BIONTECH SE
0,34% | 31.12.2023 | 815 263 ( 0,34% ) | 75 Mio $ | 31.03.2024 |
Aktive Positionen von Sean Marett
Unternehmen | Position | Beginn |
---|---|---|
BIONTECH SE | Corporate Officer/Principal | 01.01.2012 |
JPT Peptide Technologies GmbH
JPT Peptide Technologies GmbH Medical SpecialtiesHealth Technology JPT Peptide Technologies GmbH provides innovative peptide based products and services for vaccine development, immune monitoring and peptide biomarker discovery. The firm’s products include custom peptides, modified & labeled peptides, clinical peptides, stable isotope-labeled peptides, SPOT peptides, immunogenic peptides, peptide libraries, peptide pools, peptide microarrays, peptide ELISA, enzyme profiling and epitope discovery service. The company was founded in 2004 and is headquartered in Berlin, Germany. | Chief Executive Officer | - |
PHMR Ltd.
PHMR Ltd. Information Technology ServicesTechnology Services Part of UDG Healthcare Ltd. (Dublin), PHMR Ltd. is a healthcare consulting British company that specializes in insight-enabled pricing and market access approaches to ensure successful product launch and life-cycle management. The private company is based in London, UK. The company helps its clients in the healthcare industries build value for their products by using academically-proven analytical methods to find and form clinical, economic, and humanistic evidence. PHMR is an international team of highly qualified health economists and research scientists. The company was founded by Mark Ratcliffe, who has been the CEO since incorporation. PHMR was acquired by UDG Healthcare Ltd. (Dublin) on January 26, 2021 for $43.75 million. | Chairman | 01.01.2017 |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Director/Board Member | 01.02.2021 |
Ehemalige bekannte Positionen von Sean Marett
Unternehmen | Position | Ende |
---|---|---|
KWS BioTest Ltd.
KWS BioTest Ltd. Pharmaceuticals: MajorHealth Technology KWS BioTest Ltd. provides preclinical pharmacology and drug development for human diseases. Its capabilities include clinical biomarkers, cell biology, bioanalytical services, in vivo pharmacology, vaccine development. The company was founded by Williams A. Neil and Trevor Langley in 2004 and is headquartered in Bristol, the United Kingdom. | Director/Board Member | 01.01.2018 |
Mann Bioinvest Ltd.
Mann Bioinvest Ltd. Financial ConglomeratesFinance Mann Bioinvest Ltd. invests in the life science sector. The company was founded by James Mellon in 2012 and is headquartered in Douglas, the United Kingdom. | Director/Board Member | 01.01.2016 |
GSK PLC | Corporate Officer/Principal | - |
PFIZER, INC. | Corporate Officer/Principal | - |
UCB Celltech
UCB Celltech BiotechnologyHealth Technology Part of UCB SA, UCB Celltech is a British company that develops novel therapeutic products for humans. The private company is based in Slough, UK and was founded in 2006. | Corporate Officer/Principal | - |
Ausbildung von Sean Marett
King's College London | Undergraduate Degree |
Manchester Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
PFIZER, INC. | Health Technology |
GSK PLC | Health Technology |
EVOTEC SE | Health Technology |
BIONTECH SE | Health Technology |
Private Unternehmen | 9 |
---|---|
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
Lorantis Ltd.
Lorantis Ltd. Pharmaceuticals: MajorHealth Technology Lorantis Ltd. used to discover and develop drugs. The company had discovered a fundamental immune mechanism, by which the immune response to any disease-causing antigen may be suppressed. It used pursue immunology drug discovery and development programmes to address unmet medical needs. Lorantis was founded in 1998 and was headquartered in Cambridge, UK | Health Technology |
NextPharma Technologies Ltd.
NextPharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology NextPharma Technologies, In. develops, manufactures, packages, and distributes pharmaceutical products and formulations. The firm focuses on lyophilization, sterile fill finish and pellet technologies, and in product manufacturing including cyotoxics, hormones, penicillins, cephalosporins, and controlled drugs. The company was established on October 27, 2000 and is headquartered in London, the United Kingdom. | Health Technology |
KWS BioTest Ltd.
KWS BioTest Ltd. Pharmaceuticals: MajorHealth Technology KWS BioTest Ltd. provides preclinical pharmacology and drug development for human diseases. Its capabilities include clinical biomarkers, cell biology, bioanalytical services, in vivo pharmacology, vaccine development. The company was founded by Williams A. Neil and Trevor Langley in 2004 and is headquartered in Bristol, the United Kingdom. | Health Technology |
JPT Peptide Technologies GmbH
JPT Peptide Technologies GmbH Medical SpecialtiesHealth Technology JPT Peptide Technologies GmbH provides innovative peptide based products and services for vaccine development, immune monitoring and peptide biomarker discovery. The firm’s products include custom peptides, modified & labeled peptides, clinical peptides, stable isotope-labeled peptides, SPOT peptides, immunogenic peptides, peptide libraries, peptide pools, peptide microarrays, peptide ELISA, enzyme profiling and epitope discovery service. The company was founded in 2004 and is headquartered in Berlin, Germany. | Health Technology |
UCB Celltech
UCB Celltech BiotechnologyHealth Technology Part of UCB SA, UCB Celltech is a British company that develops novel therapeutic products for humans. The private company is based in Slough, UK and was founded in 2006. | Health Technology |
Mann Bioinvest Ltd.
Mann Bioinvest Ltd. Financial ConglomeratesFinance Mann Bioinvest Ltd. invests in the life science sector. The company was founded by James Mellon in 2012 and is headquartered in Douglas, the United Kingdom. | Finance |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The private company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Commercial Services |
PHMR Ltd.
PHMR Ltd. Information Technology ServicesTechnology Services Part of UDG Healthcare Ltd. (Dublin), PHMR Ltd. is a healthcare consulting British company that specializes in insight-enabled pricing and market access approaches to ensure successful product launch and life-cycle management. The private company is based in London, UK. The company helps its clients in the healthcare industries build value for their products by using academically-proven analytical methods to find and form clinical, economic, and humanistic evidence. PHMR is an international team of highly qualified health economists and research scientists. The company was founded by Mark Ratcliffe, who has been the CEO since incorporation. PHMR was acquired by UDG Healthcare Ltd. (Dublin) on January 26, 2021 for $43.75 million. | Technology Services |